Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027651 (
tumor
)
685,946
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The growth and metastatic behavior of three human
tumor
cell lines and a human colon carcinoma previously passaged in vivo were compared between nude mice and scid mice after xenotransplantation. The three human
tumor
lines included a bladder carcinoma (T24B), a melanoma (RPMI 7931) and a lacZ gene-transduced breast cancer (MDA-MB-435 BAG). The lacZ gene codes for beta-galactosidase, which can be stained blue with chromogenic substrate X-gal, thus allowing the highly sensitive detection and quantitative examination of human cancer metastasis in host mice. Adult (7-14 weeks) NMRI nude and C.B-17
SCID
mice were inoculated with 0.5-5 x 10(6)
tumor
cells s.c. Comparable take rate, latent period and growth rate of implanted tumors were observed in nude and scid mice for each of the cell lines tested. At the time of autopsy, which varied from 6 to 11 weeks after inoculation, a significantly higher incidence of spontaneous lung metastasis was discovered in scid mice (96%) than in age-matched nude mice (27%, total P less than 0.001). In vitro assays for NK cell-mediated cytotoxicity revealed no significant differences between the two strains of mice. Our results suggest that nude and scid mice are equally suitable for propagating human tumors. However, the metastatic capacity of human
tumor
cells appears to be better expressed in scid mice. Scid mice may therefore provide an advantageous model for the study of human
tumor
metastasis.
...
PMID:Comparative studies between nude and scid mice on the growth and metastatic behavior of xenografted human tumors. 158 90
Tumor
-reactive antibodies coupled to ricin or its A-chain (immunotoxins) have been used in rodents and humans to treat a variety of neoplastic diseases. Side-effects of such treatment include hepatotoxicity, vascular leak syndrome, myalgia and low grade fever. At high doses, severe toxicities include liver damage, pulmonary edema, aphasia, rhabdomyolysis and kidney failure. There have been a limited number of toxicologic studies on uncoupled ricin or its A-chain and none on deglycosylated A-chain. Since the latter has been utilized in "second generation" immunotoxins, the current studies were carried out to evaluate the toxicities induced by deglycosylated ricin A-chain (dgA) in mice. The administration of dgA to normal BALB/c mice causes early (24 h) weight loss and late (10 day) accumulation of ascites. These effects could be partially altered by changing the route of injection of dgA from i.v. to i.p. Thus, i.p. administration caused weight loss but not ascites, whereas i.v. administration caused both. Weight loss was associated with reduced fluid intake by the treated mice, and was not associated with increased levels of serum TNF-alpha.
SCID
mice injected with the same dose of dgA as normal BALB/c mice developed ascites, but it was of lesser severity, suggesting that a functional immune system, differences in microbial flora, or strain differences may be involved in the development of ascites.
...
PMID:The toxicity of chemically deglycosylated ricin A-chain in mice. 162 27
Myeloma is one of the interleukin (IL)-6-related diseases to which abnormal expression of IL-6 has been reported to be linked. We examined the in vivo inhibitory effect of anti-human IL-6 receptor (IL-6R) antibody on human myeloma cell growth in mice.
SCID
mice were subcutaneously inoculated with solid tumor of the myeloma cell line S6B45 in which human IL-6 was acting as an autocrine growth factor. Ten intraperitoneal administrations of 100 micrograms of the anti-human IL-6R antibody PM1 at 48-h intervals strongly inhibited the growth of S6B45 cells when the administration started 24 h after
tumor
inoculation. The tumor growth inhibition in vivo was also observed by administration of the anti-human IL-6 antibody MH166 using the same procedure as for PM1. The inhibitory effect of PM1 was not significant when the administration started 5 or more days after
tumor
inoculation. This work indicates that anti-human IL-6R antibody, as well as anti-human IL-6 antibody inhibits human myeloma growth in vivo, and provides an animal model for testing the therapeutic value of agents such as antibodies to human IL-6, IL-6R and gp130, an IL-6R-associated signal transducer, in the treatment of human myelomas.
...
PMID:Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo. 163 1
Aggressive B-cell lymphomas are occurring with increasing incidence among individuals infected with human immunodeficiency virus (HIV). Several lines of evidence implicate both Epstein-Barr virus (EBV) and c-myc activation in the pathogenesis of a major subset of these tumors. These observations prompted our investigation of interactions among EBV, c-myc, and HIV in primary B cells. We show that nonimmortalized peripheral B lymphocytes from EBV-seropositive, HIV-seronegative donors can be infected by HIV and that a subset of these lymphocytes become transformed. Malignant transformation was documented by several criteria. These cells displayed altered growth properties, propagating in 1% serum and cloning in soft agar, and formed invasive tumors of Burkitt lymphoma phenotype after subcutaneous injection into
severe combined immunodeficiency
mice. Such cells revealed marked enhancement of EBV DNA and RNA and of endogenous c-myc transcripts and protein. HIV-1 infection of already immortalized B-cell lines led to a similar upregulation of EBV and c-myc transcripts. These data indicate that HIV has properties of a transforming retrovirus, as it mediates two events linked to B-cell
neoplasia
: deregulation of c-myc and activation of EBV. They also raise the possibility of a role for HIV, apart from induction of immune suppression, in the pathogenesis of B-cell lymphoma in the acquired immune deficiency syndrome.
...
PMID:Human immunodeficiency virus induction of malignant transformation in human B lymphocytes. 165 56
Epstein--Barr virus (EBV) is a latent human herpes virus that growth-transforms EBV receptor/CD21+ B cells and is associated with several high-frequency malignancies. Reactivation of latent EBV occurs in approximately 1/3 of organ graft recipients and a majority of AIDS patients; EBV-positive B lymphoproliferative lesions represent often fatal complications in organ transplantation and late-stage AIDS. Although such lymphomas can arise from endogenous virus, the high
tumor
risk in EBV-seronegative transplant recipients implies de novo infection, in particular virus transmission with intra-graft B lymphocytes. Since
SCID
mice engrafted with human lymphocytes (SCIDhum) typically develop endogenous EBV+ (human) tumors in their graft it is difficult to study exogenous virus transmission in this model. We here demonstrate that beige/nude/xid mice engrafted with human lymphoid cells (BNXhum) selectively accept human B but not T cell grafts. Unexpectedly these mice fail to develop endogenous lymphomas observed in SCIDhum mice engrafted in parallel. However, injection of as few as less than 500 EBV particles produces rapidly fatal, polyclonal lymphomas in BNXhum animals. This virus sensitivity of BNXhum approaches conditions for EBV transmission with organ grafts.
...
PMID:Exogenous but not endogenous EBV induces lymphomas in beige/nude/xid mice carrying human lymphoid xenografts. 165 5
Epstein-Barr virus (EBV) carrying malignant lymphomas of the central nervous system are increasing owing to the increasing numbers of immunodeficient patients. To further understand the pathogenesis of these tumors, we studied the invasiveness of four EBV-immortalized lymphoblastoid cell lines in the brains of immunodeficient mice and the expression of adhesion molecules during this process. We injected four EBV-infected human lymphoblastoid cell lines intracerebrally into nude as well as
SCID
/
SCID
CB17 mice. Within 13 to 14 days, lethal brain lymphoproliferative lesions resulted in
SCID
mice, whereas similar lesions developed in 21 to 24 days in nude mice. Atypical large lymphoid cells aggressively infiltrated brain parenchyma, ventricular, and subarachnoid spaces. No difference in invasiveness was found between the monoclonal lymphoblastoid cell lines grown in long-term culture and polyclonal lymphoblastoid cell lines grown for a shorter duration.
Tumors
retained the same human immunoglobulin expression and activation antigen profile as the original cell lines. Furthermore, tumors expressed human LFA-1/ICAM-1 and the
tumor
blood vessels strongly expressed murine ICAM-1, but not MECA 79. Mice injected intracerebrally with peripheral blood leukocytes or normal bone marrow cells from an EBV seronegative individual failed to form tumors confirming the pivotal role for EBV in this process.
SCID
mice offer advantages for studying central nervous system lymphoproliferative disease.
...
PMID:SCID/human mouse model of central nervous system lymphoproliferative disease. 168 2
We reasoned that the
SCID
-hu mouse could provide an appropriate lymphoid or stromal microenvironment to support the growth of primary human lymphoma. Heterotransplantation of nine cases of primary T-cell non-Hodgkin's lymphoma (NHL) into untreated
SCID
mice and
SCID
mice reconstituted with human fetal thymus, spleen, and liver (SCID-hu) resulted in the development of lymphoid tumors in five (56%) cases. Two clonal T-cell NHL grew after a mean of 90 days after injection of primary lymphoma cell suspensions into the thymus xenografts in
SCID
-hu mice and failed to grow in a variety of sites in
SCID
mice, except for small tumors that developed after a long (157-day) latency period after intracranial injection of
tumor
cell suspensions into weanling
SCID
mice. Successful serial transplantation of NHL in
SCID
and
SCID
-hu mice required the presence of a human lymphoid or
tumor
microenvironment, and was enhanced by pretreating the
SCID
mice with 175 rad radiation and antiasialo antisera. Analysis of the primary and transplanted T-cell tumors showed identical patterns of T-cell surface markers by flow cytometry and immunophenotyping of fixed tissue sections, and, in one case, reactivity with a specific monoclonal antibody to V beta 5.1. Genotyping of the transplanted tumors showed T-cell receptor gene rearrangements identical to those present in the primary tumors. In one case, the presence of Epstein-Barr virus-positive B cells in association with the primary tumor resulted in the growth of a lymphoblastoid B-cell neoplasm in addition to the malignant T-cell lymphoma after transplantation of
tumor
fragments to
SCID
mice. The data support the hypothesis that a human lymphoid microenvironment enhances the growth of T-cell NHL in
SCID
mice. The
SCID
-hu thymus graft provides an apparently unique microenvironment that supports the growth of primary T-cell NHL, and can be used to study the interaction between lymphoma cells, nontransformed lymphoid cells, and the surrounding stromal microenvironment in vivo.
...
PMID:Growth of primary T-cell non-Hodgkin's lymphomata in SCID-hu mice: requirement for a human lymphoid microenvironment. 182 59
When human peripheral blood lymphocytes (PBLs) from Epstein-Barr virus (EBV)-seropositive donors are injected intraperitoneally into
SCID
mice, EBV+ B cell tumors develop within weeks. A preliminary report (Mosier, D. E., R. J. Gulizia, S. M. Baird, D. D. Richman, D. B. Wilson, R. I. Fox, and T. J. Kipps, 1989. Blood. 74(Suppl. 1):52a) has suggested that such tumors resemble the EBV-positive malignancy, Burkitt's lymphoma. The present work shows that generally the human (hu) PBL-
SCID
tumors are distinct from Burkitt's lymphoma and instead resemble lymphoblastoid cell lines (LCLs) generated by EBV-infection of normal B cells in vitro in terms of: (a) their cell surface phenotype, with expression of B cell activation antigens and adhesion molecules, (b) normal karyotype, and (c) viral phenotype, with expression of all the transformation-associated EBV latent proteins and, in a minority of cells, productive cycle antigens. Indeed, in vitro-transformed LCLs also grow when inoculated into
SCID
mice, the frequency of
tumor
outgrowth correlating with the in vitro growth phenotype of the LCL which is itself determined by the identity of the transforming virus (i.e., type 1 or type 2 EBV). Histologically the PBL-derived hu-
SCID
tumors resemble the EBV+ large cell lymphomas that develop in immuno-suppressed patients and, like the human tumors, often present at multiple sites as individual monoclonal or oligoclonal foci. The remarkable efficiency of
tumor
development in the hu-
SCID
model suggests that lymphomagenesis involves direct outgrowth of EBV-transformed B cells without requirement for secondary genetic changes, and that selection on the basis of cell growth rate alone is sufficient to explain the monoclonal/oligoclonal nature of
tumor
foci. EBV+ large cell lymphoma of the immunosuppressed may arise in a similar way.
...
PMID:Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. 184 72
Cryopreserved cell suspensions of freshly excised melanoma metastases from nine patients were injected s.c. into C.B-17
severe combined immunodeficiency
(
SCID
) mice. All 9 tumors grew as s.c. masses and six of nine were successfully transplanted into other
SCID
mice. Transplant inocula as low as 5 x 10(5) cells resulted in 100%
tumor
incidence. Moreover, seven of nine tumors metastasized, five from the original s.c. implants and two from transplanted s.c. tumors. Metastases were detected mainly in the lungs but also were found in abdominal viscera (liver, spleen, and pancreas) and thoracic lymph nodes. Flow cytometric analysis showed that expression of a panel of melanoma antigens, melanoma-associated proteoglycan, ganglioside GD3, and ganglioside GD2, was maintained with
SCID
passage. The original
tumor
inocula contained a variable percentage of
tumor
-associated lymphocytes (1-76%). Flow cytometry analysis indicated that these were mainly CD3+ T-cells. However, there was no correlation between the percentage of
tumor
-associated lymphocytes and the time required for development of a palpable
tumor
after s.c. injection or the ability to metastasize. These results demonstrate the growth and spontaneous metastasis of fresh human melanoma in
SCID
mice and suggest that this model could be important for therapeutic and basic biological studies.
...
PMID:Growth and metastasis of fresh human melanoma tissue in mice with severe combined immunodeficiency. 189 83
In vivo studies on human malignant tumors are limited because of a lack of suitable animal models. In this study, the usefulness of
SCID
(
severe combined immunodeficiency
) mice, deficient in functions of both T- and B-lymphocytes, was evaluated. Inbred
SCID
mice were kept in isolated cages and 2 x 10(7) cells of KU-7, an established bladder carcinoma cell line, were inoculated in the subcutaneous tissue of the flank region of six
SCID
mice. Athymic nude mice were inoculated by the same method and served as the controls. The KU-7 cells were taken within 14 days in the injected region in all six
SCID
mice, while in only five out of eight nude mice.
Tumors
subsequently formed at the site of inoculation in these mice were confirmed to be transitional cell carcinomas histologically and intra-abdominal metastases were noted in two
SCID
mice. We conclude that
SCID
mice provide an ideal in vivo model for experimental studies of human urologic malignant tumors.
...
PMID:SCID mice: a suitable model for experimental studies of urologic malignancies. 189 40
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>